These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16257785)

  • 1. Role of neoadjuvant androgen deprivation before radical prostate radiotherapy.
    Parker C
    Lancet Oncol; 2005 Nov; 6(11):819-21. PubMed ID: 16257785
    [No Abstract]   [Full Text] [Related]  

  • 2. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.
    Langenhuijsen JF; van Lin EN; Hoffmann AL; Spitters-Post I; Alfred Witjes J; Kaanders JH; Mulders PF
    Urol Oncol; 2011; 29(1):52-7. PubMed ID: 19523856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
    Higgins GS; McLaren DB; Kerr GR; Elliott T; Howard GC
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):982-9. PubMed ID: 16750310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
    Malik R; Jani AB; Liauw SL
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
    J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation before prostate radiotherapy: how long is long enough?
    Parker C
    Lancet Oncol; 2011 May; 12(5):411-2. PubMed ID: 21440506
    [No Abstract]   [Full Text] [Related]  

  • 7. Why does androgen deprivation enhance the results of radiation therapy?
    Wo JY; Zietman AL
    Urol Oncol; 2008; 26(5):522-9. PubMed ID: 18774467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate].
    Mazeron JJ; Simon JM; Toubiana T; Lang P
    Bull Cancer; 2005 Dec; 92(12):1078-84. PubMed ID: 16396754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.
    Sonpavde G; Palapattu GS
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):439-50. PubMed ID: 20214524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neoadjuvant hormonal treatment combined with external irradiation in the management of prostate cancer].
    Bolla M; Artignan X; Fourneret P; Brochon D; Ringeisen F; Descotes JL
    Bull Cancer; 2006 Nov; 93(11):1101-5. PubMed ID: 17145579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer.
    Roach M
    Eur Urol; 1997; 32 Suppl 3():48-54. PubMed ID: 9267785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.
    D'Amico AV
    J Clin Oncol; 2007 Jan; 25(1):8-9. PubMed ID: 17194901
    [No Abstract]   [Full Text] [Related]  

  • 19. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In regard to Drs. Shipley et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol 86-10.
    Sethi TK; Negi PS; Rawat S
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1510; author reply 1510. PubMed ID: 14630292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.